Right now, state policy regarding medical marijuana use is out ahead of the science, which can lead to predicaments where cannabis is prescribed in situations where it is not needed, explained Kevin P. Hill, MD, MHS, of Beth Israel Deaconess Medical Center and Harvard Medical School.
Right now, state policy regarding medical marijuana use is out ahead of the science, which can lead to predicaments where cannabis is prescribed in situations where it is not needed, explained Kevin P. Hill, MD, MHS, of Beth Israel Deaconess Medical Center and Harvard Medical School.
Transcript
What messages do payers give physicians in response to the rise in legal marijuana?
I think there are areas where it's, unfortunately, predicaments where the policy is ahead of the science. So I talked earlier about a handful of conditions: 3 beyond the 2 FDA-approved conditions. But when you look at the 29 states and the District that have medical cannabis policies, there are over 50 conditions for which various states say cannabis is effective. So I think a lot of times we have people who really are desperate, they want to have effective treatments available, but they're launching ahead using cannabinoids in ways that really haven't been shown to be effective in rigorous clinical trials. And so I think that's unfortunate.
A typical example is, in my field, in substance use disorders, there are people who say that cannabis could be an exit drug, and exit strategy for people using opioids or addicted to opioids. And my initial concern about that is that we actually have 3 FDA-approved medications for opioid use disorders that do actually work fairly well. And so I would be concerned if I knew that a patient who had opioid use disorder was being treated with cannabis as opposed to one of those 3 FDA-approved treatments.
I think there's a right way and a wrong way to do this, and when you have policy out in front of the science, and people launching ahead with these policies, sometimes they're doing it in the wrong way.
Valoctocogene Roxaparvovec Dramatically Reduces Bleeding in Hemophilia A
May 15th 2024New study findings demonstrate that valoctocogene roxaparvovec, a gene therapy for severe hemophilia A, significantly reduces bleeding episodes and dependency on factor VIII infusions over a 3-year period, while maintaining a favorable safety profile.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen